ResMed Inc. $RMD Shares Purchased by National Pension Service

National Pension Service raised its position in ResMed Inc. (NYSE:RMD) by 0.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 232,873 shares of the medical equipment provider’s stock after purchasing an additional 1,652 shares during the quarter. National Pension Service owned about 0.16% of ResMed worth $60,081,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Zions Bancorporation National Association UT bought a new stake in ResMed during the 1st quarter valued at $45,000. Groupe la Francaise acquired a new position in shares of ResMed during the first quarter valued at $45,000. Harbour Investments Inc. increased its holdings in shares of ResMed by 264.2% during the second quarter. Harbour Investments Inc. now owns 244 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 177 shares during the period. Larson Financial Group LLC lifted its holdings in ResMed by 926.7% in the first quarter. Larson Financial Group LLC now owns 308 shares of the medical equipment provider’s stock worth $69,000 after purchasing an additional 278 shares during the period. Finally, Quarry LP grew its position in ResMed by 141.1% in the 1st quarter. Quarry LP now owns 311 shares of the medical equipment provider’s stock valued at $70,000 after buying an additional 182 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

Insider Transactions at ResMed

In other news, Director Witte Jan De sold 487 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $250.25, for a total value of $121,871.75. Following the completion of the transaction, the director owned 5,319 shares in the company, valued at approximately $1,331,079.75. This represents a 8.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Michael J. Rider sold 100 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $274.36, for a total transaction of $27,436.00. Following the transaction, the general counsel directly owned 11,327 shares of the company’s stock, valued at $3,107,675.72. The trade was a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 21,182 shares of company stock worth $5,658,783. 0.65% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently commented on RMD shares. William Blair raised ResMed to a “strong-buy” rating in a research note on Friday, August 1st. Wall Street Zen lowered shares of ResMed from a “buy” rating to a “hold” rating in a research note on Sunday, August 10th. Royal Bank Of Canada upped their price target on ResMed from $300.00 to $303.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Wells Fargo & Company started coverage on ResMed in a research report on Monday, October 13th. They set an “equal weight” rating and a $280.00 target price on the stock. Finally, Robert W. Baird cut their price objective on ResMed from $320.00 to $300.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $297.45.

ResMed Stock Down 0.4%

RMD opened at $251.91 on Friday. The company has a market capitalization of $36.76 billion, a PE ratio of 26.49, a price-to-earnings-growth ratio of 1.75 and a beta of 0.87. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.44 and a quick ratio of 2.53. ResMed Inc. has a fifty-two week low of $199.92 and a fifty-two week high of $293.81. The business has a 50-day moving average of $266.91 and a 200-day moving average of $262.73.

ResMed (NYSE:RMD) last posted its earnings results on Friday, October 31st. The medical equipment provider reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. ResMed had a net margin of 27.22% and a return on equity of 25.62%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.20 earnings per share. Equities research analysts forecast that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Thursday, November 13th will be paid a $0.60 dividend. The ex-dividend date is Thursday, November 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.0%. ResMed’s payout ratio is presently 24.56%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.